Marksans Pharma shines as its Goa facility gets Australian TGA’s nod to manufacture pharmaceutical formulations
Marksans Pharma is currently trading at Rs. 217.40, up by 10.40 points or 5.02% from its previous closing of Rs. 207.00 on the BSE.
The scrip opened at Rs. 211.45 and has touched a high and low of Rs. 219.35 and Rs. 207.65 respectively. So far 108245 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 358.50 on 02-Dec-2024 and a 52 week low of Rs. 130.15 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 219.35 and Rs. 190.05 respectively. The current market cap of the company is Rs. 9885.77 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 26.26% and 29.87% respectively.
Marksans Pharma has received approval from Australian TGA for its manufacturing facility located at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa for manufacture of pharmaceutical formulations in solid dosage forms of tablets and hard capsules for Australian markets. The products will be manufactured at the above facility in Goa, India and marketed & distributed in Australian markets through the company’s subsidiary Nova Pharmaceuticals Australasia.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
